Reovirus enhances cytotoxicity of natural killer cells against colorectal cancer via TLR3 pathway.

Background: Cetuximab has been approved for use for first-line treatment of patients with wild-type KRAS metastatic colorectal cancer (CRC). However, treatment with cetuximab has shown limited efficacy as a CRC monotherapy. In addition, natural killer (NK) cell function is known to be severely attenuated in cancer patients.

A Comparative Analysis of Methods for Titering Reovirus.

Background: A key challenge in the process of virus amplification is the need for a simple and convenient method for measuring virus titers.

Objective: Real-time unlabeled cell analysis (RTCA) was used to establish a standard curve of correlation between half-cell index time (CIT) and virus titer. At the same time, the virus titer from tunable resistance pulse detection (TRPS) technology was compared with the traditional median tissue culture infectious dose (TCID) method to evaluate the feasibility and application value of the RTCA technique and TRPS technology.